BioSpace News Archive

Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced today their participation in The American Society for Neural Therapy and Repair Annual Conference from April 27-30, 2023 in Clearwater, FL.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

GL CHEMTEC (“GLC”) today announced the formation of its Scientific Advisory Board comprised of distinguished leaders in Small Molecule R&D (Chemistry/Biology), Process Development & Scale-Up, Green Chemistry, Medical Devices and Drug Delivery.

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that it will host a company presentation at the 2023 Bloom Burton & Co. Healthcare Investor Conference to be held in Toronto, Ontario from April 25-26, 2023.

Qualigen Therapeutics, Inc. reports that on April 20, 2023, it received a letter from the Nasdaq Stock Market LLC relating to the Company’s failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2022 as required under Section 5250 of Nasdaq Rules regarding the Qualification, Listing and Delisting of Companies.

Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced U.S. Food and Drug Administration (FDA) approval of its MiniMed™ 780G system with the Guardian™ 4 sensor requiring no fingersticks while in SmartGuard™ technology.

RetinAI Medical AG, a leader in clinical and imaging data management software and advanced analytics using artificial intelligence for ophthalmology, is excited to announce a new partnership with Boehringer Ingelheim.

NovaBay Pharmaceuticals Launches DERMAdoctor’s New Comfort + Joy Psoriasis Therapeutic Moisturizing Cream on the QVC ® Network.

Apellis Pharmaceuticals, Inc. today announced that the company has received validation of its marketing applications by regulatory authorities in Canada, Australia, the United Kingdom, and Switzerland for intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

XORTX Therapeutics Inc. is pleased to announce the grant of Orphan Drug Designation for oxypurinol – “orphan-drug designation request of oxypurinol is granted for treatment of autosomal dominant polycystic kidney disease”.